Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00613119 · ClinicalTrials.gov registry record
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia
A clinical trial of Dementia and Frontotemporal Lobar Degeneration, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- 108
- Enrollment target
- 1
- Study location
NCT00613119 is a study of Dementia and Frontotemporal Lobar Degeneration that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 108 participants, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00613119, a study of Dementia and Frontotemporal Lobar Degeneration, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- 108 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will use positron emission tomography (PET) imaging to measure a receptor in the brain that is involved in inflammation. Certain neurological disorders, possibly including frontotemporal dementia (FTD), are associated with increased inflammation in the brain. This study may help elucidate the relationship between FTD and inflammation. Patients with FTD and healthy volunteers who are 35 years of age or older may be eligible for this study. Candidates are screened with a medical history, physical examination, electrocardiogram, and blood and urine tests. Participants undergo the following procedures: * Whole body PET scan: PET uses small amounts of a radioactive chemical called a tracer that labels active areas of the brain so the activity can be seen with a special camera. The tracer used in this study is \[11C\]PBR28. Before starting the scan, a catheter (plastic tube) is placed in a vein in the arm to inject the tracer. Pictures are taken for 1 hour. This short scan is done to determine if \[11C\]PBR28 binds to the subject s receptors, since a number of people do not have binding. Subjects who have binding continue with brain PET and MRI scans, described below. * Brain PET imaging: Before starting the scan, a catheter is placed in a vein in the arm to inject the tracer,\<TAB\> and another catheter is placed in an artery in the wrist to obtain blood samples during the scan. The subject lies on the scanner bed. A special mask is fitted to the head and attached to the bed to help keep the person s head still during the scan so the images will be clear. An 8-minute transmission scan is done just before the tracer is injected to provide measures of the brain that are helpful in calculating information from subsequent scans. After the tracer is injected, pictures are taken for about 2.5 hours, while the subject lies still on the scanner bed. * Blood and urine tests are done the day of and the day following each PET scan. * Magnetic resonance imaging (MRI):
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2008-01-31 |
| Est. Completion | 2017-07-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00613119
The ClinicalTrials.gov registry entry for NCT00613119 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 108 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,722-participant average among 199 other Dementia trials with a reported enrollment target (99% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dementia appearing as the primary indexed condition, and to 0 interventions.
NCT00613119 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00613119 about?
NCT00613119 is a clinical study titled "PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in Frontotemporal Dementia". This study will use positron emission tomography (PET) imaging to measure a receptor in the brain that is involved in inflammation. Certain neurological disorders, possibly including frontotemporal dementia (FTD), are associated with increased inflammation in the brain. This study may help elucidate...
What is the current status of trial NCT00613119?
This trial is currently completed. The enrollment target is 108 participants. The study started on 2008-01-31. Estimated completion is 2017-07-13.
What conditions does trial NCT00613119 study?
This clinical trial studies the following conditions: Dementia, Frontotemporal Lobar Degeneration.
Who is sponsoring clinical trial NCT00613119?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00613119 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dementia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dynamic Light Scattering Ocular Measurement in the Detection of Dementia
RECRUITING
-
Ferritin and Iron Burden in SAH sIRB
RECRUITING · Phase 1
-
δ in Dementia Clinical Trials
RECRUITING · NA
-
Door-Through-Door Companion Rideshare Technology for Individuals With Alzheimer's Disease and Related Dementias (AD/ADRD)
RECRUITING · Phase 1
-
Caregiver as Navigator: Develop Skills Online (CAN-DO)
RECRUITING · NA
-
Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.